• 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999; 189: 17.
  • 3
    Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997; 226: 248257; discussion,257–260.
  • 4
    Evans DB, Pisters PW, Lee JE, et al. Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. J Hepatobiliary Pancreat Surg. 1998; 5: 242250.
  • 5
    Maheshwari V, Moser AJ. Current management of locally advanced pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 356364.
  • 6
    Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981; 48: 17051710.
  • 7
    Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006; 24: 11451151.
  • 8
    Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002; 52: 12931302.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 63: 457481.
  • 10
    Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B. 1972; 34: 187220.
  • 11
    Peto R, Peto J. Asymptotically efficient rank invariant procedures (with discussion). J R Stat Soc. 1972; Series A 135: 185.
  • 12
    [No authors listed] Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988; 80: 751755.
  • 13
    Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002; 81: 138143.
  • 14
    Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003; 57: 98104.
  • 15
    McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001; 19: 42024208.
  • 16
    Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001; 51: 974981.
  • 17
    Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34: 107116.
  • 18
    Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004; 27: 5156.
  • 19
    Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. Int J Radiat Oncol Biol Phys. 2002; 54: 137141.
  • 20
    Viret F, Ychou M, Goncalves A, et al. Docetaxel and radiotherapy and pancreatic cancer. Pancreas. 2003; 27: 214219.
  • 21
    Wilkowski R, Thoma M, Heinemann V, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer—feasible and effective [in German]. Strahlenther Onkol. 2003; 179: 7886.
  • 22
    Brunner TB, Grabenbauer GG, Klein P, et al. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 144153.
  • 23
    Cohen SJ, Dobelbower RJr, Lipsitz S, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 2005; 62: 13451350.
  • 24
    Kornek GV, Potter R, Selzer E, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys. 2001; 49: 665671.
  • 25
    Azria D, Ychou M, Jacot W, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas. 2002; 25: 360365.
  • 26
    Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004; 22: 26102616.
  • 27
    Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006; 24: 656662.
  • 28
    Crane CH, Mason K, Janjan NA, Milas L. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol. 2003; 26: S81S84.
  • 29
    Zimmermann FB, Jeremic B, Lersch C, Geinitz H, Hennig M, Molls M. Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas. Hepatogastroenterology. 2005; 52: 246250.
  • 30
    Ben-Josef E, Shields AF, Vaishampayan U, et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 454459.
  • 31
    Spalding AC, Vineberg K, Jablonowski M, et al. Intensity modulated radiation therapy optimization with equivalent uniform dose allows substantial dose-escalation in pancreas cancer [abstract]. Int J Radiat Oncol Biol Phys. 2005; 63: S59S60.
  • 32
    Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: an FFCD-SFRO study [abstract]. J Clin Oncol 2006. 2006; 24: 4008.
  • 33
    Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004; 100: 23472354.
  • 34
    Swisher SG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003; 57: 120127.
  • 35
    Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001; 92: 279286.
  • 36
    Calvo FA, Serrano FJ, Diaz-Gonzalez JA, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol. 2006; 17: 11031110.
  • 37
    Ajani JA, Winter KA, Gunderson LL, et al. Intergroup RTOG 98–11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal [abstract]. J Clin Oncol. 2006; 24: 4009.
  • 38
    Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997; 15: 928937.
  • 39
    Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998; 16: 38433850.
  • 40
    Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs gemcitabine (G) for resected pancreatic adenocarcinoma [abstract]. J Clin Oncol. 2006; 24: 4007.